&ldquo We are pleased to test our technology in Singapore. Through partnerships with the healthcare service providers, we hope to expand this automation system regionally. The automated system can be used for any type of lateral flow point of care and not limited to only COVID-19&rdquo , said Mr Eddie Chng, the Managing Director and CEO of DLL. DLL has licensed the saliva-based ART kit IP from Duke-NUS Medical School and SingHealth. The kit, known as Parallel Amplified Saliva rapid POint-of-caRe Test (PASPORT), uses nanoparticles to bind the virus and uniquely. It also adds as a second type of nanoparticle that binds the first set of nanoparticles to amplify the signal. This makes testing using PASPORT The Automated Machine requires users to self-register by scanning their NRIC or passport at the kiosk. Users are then required to scan the unique QR code on the ART kit on the Automated Machine to uniquely tag the ART kit to the user for track and trace purposes. Users will perform the test in front of the Automated Machine in accordance to the test steps as illustrated on the screen of the Automated Machine. Users can then insert the ART cassette into the Automated Machine and leave without having to wait for the test result. The entire process is video recorded and takes no more than 5 minutes for each user. The Automated Machine will take a photo of the ART cassette and the results are sent automatically and digitally to the rightful owners within 15 to 20 minutes after the test is completed. Each Automated Machine can handle about 10 to 15 tests per hour, operating for 24 hours a day. With the use of the Automated Machine, ART tests can be processed faster. Video recording guarantees the authenticity of the tests. Most importantly, all the ART test results cannot be tampered with as the ART cassette will have to be inserted into the Automated Machine before the result appears. more sensitive at finding and flagging the virus and allows it to be used at any time of the day, where the sensitivity of the test is not compromised even after eating or drinking. Compared to other ART, amplification enables PASPORT to be extremely sensitive. In a clinical study involving over 100 participants conducted at SGH, PASPORT&rsquo s sensitivity in detecting the virus was 97% and its specificity at 90.6%, compared to the gold standard PCR test. The invention was reviewed and published by Microchimica Acta* in November 2021.